Zacks: Analysts Set $20.00 Target Price for MAYVILLE ENGR C/SH (NYSE:MEC)

Share on StockTwits

Shares of MAYVILLE ENGR C/SH (NYSE:MEC) have earned a consensus broker rating score of 1.40 (Strong Buy) from the five brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and four have issued a strong buy recommendation on the company.

Analysts have set a 1-year consensus price target of $20.00 for the company and are predicting that the company will post $0.25 EPS for the current quarter, according to Zacks. Zacks has also assigned MAYVILLE ENGR C/SH an industry rank of 192 out of 256 based on the ratings given to related companies.

A number of brokerages recently commented on MEC. Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $23.00 to $24.00 in a research note on Monday, June 3rd. Robert W. Baird began coverage on MAYVILLE ENGR C/SH in a research note on Monday, June 3rd. They issued an “outperform” rating and a $19.00 target price for the company. William Blair began coverage on MAYVILLE ENGR C/SH in a research note on Monday, June 3rd. They issued an “outperform” rating for the company. UBS Group decreased their target price on PVH from $159.00 to $144.00 and set a “buy” rating for the company in a research note on Monday, June 3rd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 3,000 ($39.20) target price on shares of in a research note on Monday, June 3rd.

Shares of MAYVILLE ENGR C/SH stock traded up $0.17 during trading on Friday, reaching $14.52. 4,169 shares of the company were exchanged, compared to its average volume of 120,578. The company has a quick ratio of 0.84, a current ratio of 1.45 and a debt-to-equity ratio of 1.69. MAYVILLE ENGR C/SH has a twelve month low of $11.95 and a twelve month high of $17.40. The business’s 50-day simple moving average is $14.92.

MAYVILLE ENGR C/SH (NYSE:MEC) last announced its quarterly earnings data on Tuesday, May 28th. The company reported $0.18 EPS for the quarter. The company had revenue of $143.73 million for the quarter. Analysts expect that MAYVILLE ENGR C/SH will post 1.08 EPS for the current fiscal year.

In other news, Director Timothy L. Christen purchased 5,000 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $85,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Robert D. Kamphuis purchased 34,460 shares of the business’s stock in a transaction dated Thursday, June 13th. The stock was purchased at an average price of $13.00 per share, for a total transaction of $447,980.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 54,434 shares of company stock valued at $730,549.

About MAYVILLE ENGR C/SH

There is no company description available for Mayville Engineering Company Inc

Featured Article: What is a good rate of return for a mutual fund?

Get a free copy of the Zacks research report on MAYVILLE ENGR C/SH (MEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for MAYVILLE ENGR C/SH (NYSE:MEC)

Receive News & Ratings for MAYVILLE ENGR C/SH Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAYVILLE ENGR C/SH and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.